Mineralys Therapeutics, Inc. Common Stock
$ 37.14
-0.77%
26 Dec - close price
- Market Cap 2,939,258,000 USD
- Current Price $ 37.14
- High / Low $ 37.75 / 36.93
- Stock P/E N/A
- Book Value 7.30
- EPS -2.92
- Next Earning Report 2026-02-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.42 %
- 52 Week High 47.65
- 52 Week Low 8.24
About
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in Radnor, Pennsylvania, dedicated to developing innovative therapies for hypertension and other cardiovascular conditions. The company is advancing a promising pipeline of drug candidates that target significant unmet medical needs, showcasing its commitment to improving patient care and treatment outcomes. With a focus on strategic initiatives and potential market impact, Mineralys is well-positioned to significantly influence the therapeutic landscape for patients with chronic cardiovascular diseases, making it an intriguing prospect for institutional investors.
Analyst Target Price
$50.88
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-12 | 2025-05-12 | 2025-02-12 | 2024-11-11 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-07 | 2023-08-07 | 2023-05-15 | 2023-03-15 |
| Reported EPS | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 | -0.51 | -1.74 |
| Estimated EPS | -0.64 | -0.74 | -0.98 | -1.08 | -0.83 | -0.7 | -0.67 | -0.82 | -0.76 | -0.72 | -0.89 | -1.72 |
| Surprise | 0.12 | 0.08 | 0.19 | 0.1 | -0.3 | -0.13 | -0.03 | 0.21 | 0.19 | 0.41 | 0.38 | -0.02 |
| Surprise Percentage | 18.75% | 10.8108% | 19.3878% | 9.2593% | -36.1446% | -18.5714% | -4.4776% | 25.6098% | 25% | 56.9444% | 42.6966% | -1.1628% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.57 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLYS
2025-12-28 13:09:15
Mineralys (MLYS) is poised for a pivotal 2026, transitioning to a pre-commercial stage with strong Phase 3 data for lorundrostat and a robust cash position. Positive pre-NDA feedback from the FDA and JAMA recognition have de-risked the regulatory pathway, with NDA submission expected by early 2026. Despite potential commercial hurdles, the company's financial runway through 2028 and clinical demand position it as a unique opportunity.
2025-12-27 11:09:23
Swedbank AB reduced its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 22% in the third quarter, selling 84,500 shares and now owning 299,300 shares valued at approximately $11.35 million. This follows significant insider selling totaling over $61 million in the last 90 days, although insiders still retain 25.56% ownership. Analysts generally hold a "Moderate Buy" rating with an average target price of $47.43 for the company.
2025-12-26 13:09:06
Voya Investment Management LLC significantly increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 174.4% in the third quarter of 2025, now owning 138,526 shares valued at $5.25 million. This comes despite recent large insider selling, with the CEO and a director offloading shares worth over $61 million. Analysts remain largely bullish, with a consensus "Moderate Buy" rating and a target price of $47.43, even as the company reported better-than-expected earnings.
2025-12-24 10:51:00
The drug and biotech sector showed a strong comeback in late 2025 due to improved policies and M&A activity, with the biotech sector outperforming the S&P 500. This article highlights four drug/biotech stocks—Mineralys Therapeutics, Lyell Immunopharma, Insmed, and Nektar Therapeutics—that have seen significant gains of over 50% in 2025. These companies are poised for continued growth in 2026, driven by robust product portfolios and promising pipelines.
2025-12-22 07:10:00
Mineralys Therapeutics (MLYS) announced its Phase 3 Launch-HTN trial of lorundrostat for hypertension was featured in JAMA's "Research of the Year Roundup," highlighting its potential. This recognition reinforces the clinical relevance of lorundrostat, potentially strengthening the narrative for NDA discussions and commercialization, although key risks related to regulatory approval and being a single-asset biotech remain. Despite this positive visibility, investors should still consider the company's concentration risk and current valuation.
2025-12-21 21:26:00
Mineralys Therapeutics Inc. (NASDAQ: MLYS) shows divergent sentiment across all time horizons, suggesting choppy market conditions. The article highlights an exceptional 76.8:1 risk-reward short setup and provides detailed entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies. AI-generated signals indicate current price is testing resistance, with specific support and resistance levels for near-term, mid-term, and long-term outlooks.
